Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|77|1|14-17

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.1, 2010-02, pp. : 14-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

By Haq Bushra   Geyer Charles E  

Women's Health, Vol. 5, Iss. 2, 2009-03 ,pp. : 135-147

Future Medicine

Access to resources Recommend Favorite

Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab

By  

Oncology Research and Treatment, Vol. 36, Iss. 10, 2013-09 ,pp. : 554-558

Karger

Access to resources Recommend Favorite

T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 3, 2017-11 ,pp. : 216-222

Bentham Science Publishers

Access to resources Recommend Favorite

Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 14-21

Karger

Access to resources Recommend Favorite

Taxanes in adjuvant chemotherapy for early breast cancer

By Vincenzi Bruno   Santini Daniele   Tonini Giuseppe  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 323-325

Future Medicine

Access to resources Recommend Favorite